'MAGNETIC THALLIUM' FOR MRI OF ISCHEMIC HEART DISEASE

描述（申请人的摘要逐字）：第一阶段证实了可行性 EVP 1001-1的“铊磁共振成像”（MRI）。 结果显示高水平的血管增强，快速的心肌 摄取、最佳药代动力学、独特的成像特性和初步的 安全为代价的自第一阶段以来的其他结果表明， 基于EVP 1001-1增强模式的可诱导心肌缺血 在休息和压力条件下。第二阶段将扩大这些安全性， 缺血性心脏病（IHD）临床相关模型的疗效结果 并优化未来供应的准备。完成后，该代理 将为人类发展做好准备。EVP 1001-1充分利用了 MRI在IHD诊断和治疗计划方面的强大潜力， 取代更有限、更昂贵和更侵入性的检测的潜力。 拟定商业应用： 不可用

DESCRIPTION (Applicant's abstract verbatim): Phase I confirmed the feasibility of EVP 1001-1 to be the "thallium for magnetic resonance imaging" (MRI). Results demonstrated high levels of vascular enhancement, rapid myocardial uptake, optimal pharmacokinetics, unique imaging properties and preliminary safety. Additional results since Phase I suggest excellent utility for inducible myocardial ischemia based on enhancement patterns from EVP 1001-1 under rest and stress conditions. Phase II will extend these safety and efficacy results to clinically relevant models of ischemic heart disease (IHD) and optimize the preparation of future supplies. Upon completion, this agent will be ready for human development. EVP 1001-1 makes optimal use of the powerful potential of MRI for the diagnosis and treatment planning of IHD, with the potential to replace more limited, costly and invasive tests. PROPOSED COMMERCIAL APPLICATION: Not Available